Galectin-3 inhibitors as novel antithrombotic drugs with almost no bleeding risk: wishful thinking or a realistic vision?

Scheme for plasma Galectin-3 potentiating agonist-induced platelet activation and hyper-reactivity. Delineation of underlying signalling pathways. Effect of Galectin-3 inhibitor TD139 on platelet hyper-reactivity and thrombosis. Scheme for plasma Galectin-3 potentiating agonist-induced platelet activation and hyper-reactivity. Delineation of underlying signalling pathways. Effect of Galectin-3 inhibitor TD139 on platelet hyper-reactivity and thrombosis.